Our single-case experience with a heavily treated patient with HNSCC who had TP53 and BRCA2 mutations showed an unusual and prolonged response to ATO and osimertinib, suggesting the potential to target the DNA damage repair pathway in patients with HNSCC [66]. The gene discussed is TP53; the disease is head and neck squamous cell carcinoma.